Current status of precision oncology in adult glioblastoma
Autor: | Johannes Weller, Anna‐Laura Potthoff, Thomas Zeyen, Christina Schaub, Cathrina Duffy, Matthias Schneider, Ulrich Herrlinger |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2024 |
Předmět: | |
Zdroj: | Molecular Oncology, Vol 18, Iss 12, Pp 2927-2950 (2024) |
Druh dokumentu: | article |
ISSN: | 1878-0261 1574-7891 |
DOI: | 10.1002/1878-0261.13678 |
Popis: | The concept of precision oncology, the application of targeted drugs based on comprehensive molecular profiling, has revolutionized treatment strategies in oncology. This review summarizes the current status of precision oncology in glioblastoma (GBM), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. Targeted treatments without prior target verification have consistently failed. Patients with BRAF V600E‐mutated GBM benefit from BRAF/MEK‐inhibition, whereas targeting EGFR alterations was unsuccessful due to poor tumor penetration, tumor cell heterogeneity, and pathway redundancies. Systematic screening for actionable molecular alterations resulted in low rates ( |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |